Inicio>>Fz7-21 TFA

Fz7-21 TFA (Synonyms: Ac-LPSDDLEFWCHVMY-NH2 TFA)

Catalog No.GC39383

Fz7-21 (Ac-LPSDDLEFWCHVMY-NH2) TFA es un potente péptido antagonista de los receptores FZD7, se une selectivamente a la subclase FZD7 CRD y altera la conformaciÓn del CRD y la arquitectura de su ranura de uniÓn a lÍpidos. Los valores EC50 son 58 y 34 nM para FZD7 CRD humano y de ratÓn, respectivamente. Fz7-21 TFA afecta la funciÓn de FZD7 en la seÑalizaciÓn de Wnt-β-catenina y la funciÓn de células madre en organoides intestinales.

Products are for research use only. Not for human use. We do not sell to patients.

Fz7-21 TFA Chemical Structure

Tamaño Precio Disponibilidad Cantidad
5mg
261,00 $
Disponible
10mg
414,00 $
Disponible
50mg
1.215,00 $
Disponible

Tel:(909) 407-4943 Email: sales@glpbio.com

Reseñas de cliente

Based on customer reviews.

  • GlpBio Citations

    GlpBio Citations
  • Bioactive Compounds Premium Provider

    Bioactive Compounds Premium Provider

Sample solution is provided at 25 µL, 10mM.

Description Chemical Properties Product Documents Related Products

Fz7-21 TFA ((Ac)-LPSDDLEFWCHVMY-NH2 TFA), a peptide antagonist of Frizzled 7 (FZD 7) receptors, selectively binds to FZD7 CRD subclass. The EC50 values are 58 and 34 nM for human and mouse FZD7 CRD, respectively. Fz7-21 impairs Wnt/β-catenin signaling in HEK293 cells stimulated with exogenous WNT3A (IC50=100 nM) or transfected with a construct expressing WNT3A or WNT1. Fz7-21 also blocks WNT3A-mediated stabilization of β-catenin in mouse L cells (IC50=50 nM)[1].

[1]. Nile AH, et al. Publisher Correction: A selective peptide inhibitor of Frizzled 7 receptors disrupts intestinal stem cells. Nat Chem Biol. 2018 Sep;14(9):902.

Reseñas

Review for Fz7-21 TFA

Average Rating: 5 ★★★★★ (Based on Reviews and 8 reference(s) in Google Scholar.)

5 Star
100%
4 Star
0%
3 Star
0%
2 Star
0%
1 Star
0%
Review for Fz7-21 TFA

GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.

Required fields are marked with *

You may receive emails regarding this submission. Any emails will include the ability to opt-out of future communications.